Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A02700-39 | Other Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to analyze in depth the relationship of myeloid cell subpopulations during infection by Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2), the virus mediating Covid-19. Myeloid cells include neutrophils, monocytes and dendritic cells, each divided into subpopulations with different functions in immune defense and immune pathologies.
The study is based on the following hypotheses:
Infection by SARS-Cov2 drives to pneumonia in most cases, 30 percent of which require hospitalization in a pneumology ward, among which 30 percent with severe acute respiratory syndrome (SARS) must go to critical care units, with a high mortality rate.
This infection drives a strong cytokine response. In patients developing SARS, a profound, paradoxical defect in IFN alpha and in the expression of genes responding to IFN alpha was discovered. IFNs are strong anti-viral proteins, used for the treatment of viral hepatitis. Type I IFNs, including IFN alpha, have ubiquitous receptors on almost every cell type. Type III IFNs, or IFN lambda, have a more restricted receptor expression, including on neutrophils. Their polymorphisms were already related to the prognosis of another ribonucleic acid (RNA) virus with mucosal entry, hepatitis C virus (HCV), especially in people with African origins.
Coronaviruses responsible for the previous SARS-Cov or Middle East respiratory syndrome coronavirus (MERS-Cov) epidemics induce a defective IFN signal transduction. Many other viral infection lead to desensitization. Moreover, IFN alpha by itself can lead to defective antiviral responses. At the immune cell level, lymphopenia with an increased neutrophil/lymphocyte ratio were noted in severe SARS-Cov2 case. New subpopulations of neutrophils have been characterized by phenotypic and proteomic studies, with inflammatory or suppressive functions.
It will be important to know if
The answers will be obtained through the primary and secondary outcome measures, as described below.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| group 1 | Other | Former mild SARS-Cov2 Pneumonia, 2 to 12 moths before, ≤ 5 L/mn Oxygen treatment |
|
| Group 2 | Other | Former severe SARS-Cov2 Pneumonia, 2 to 12 moths before, > 5 L/mn Oxygen treatment |
|
| Group 3 | Other | Physician examination in the Pneumology ward, Cochin Hospital |
|
| Group 4 | Other | Current hospitalization for Sars-Cov2 Pneumonia at Cochin Hospital |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sampling | Other | Peripheral Blood sampling, 25 mL |
|
| Measure | Description | Time Frame |
|---|---|---|
| Myeloid cell sub-population phenotype | Cytometric analysis of surface and intracellular molecules to identify myeloid cell sub-populations and define their function in vivo | Month zero-month 36 |
| Measure | Description | Time Frame |
|---|---|---|
| Myeloid cell functions | Cell culture and cytometric and analyte analysis of their functions, including IFN production | Month zero-month 36 |
| Myeloid cell transcriptomic and proteomic study | Transcriptomic and proteomic analysis of the functions of myeloid cell subtypes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pierre-Régis Burgel, MD, PhD | Contact | 01 58 41 23 49 | +33 | pierre-regis.burgel@cch.aphp.fr |
| Marie BENHAMMANI-Godard | Contact | 01 58 41 12 11 | +33 | marie.godard@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Pierre-Régis Burgel, MD, PhD | Cochin Hospital | Principal Investigator |
Not provided
Not provided
| Label | URL |
|---|---|
| Team Niedergang | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Nasal Brushing | Other | Nasal Brushing, facultative |
|
| Month zero-month 36 |
| Transcriptomic study of nasal epithelial cells | Single cell RNA sequencing of the nasal brush products | Month zero-month 36 |
| Plasma analyte concentration measurement | High sensitivity detection by state-of-the art ELISA type methods | Month zero-month 36 |
| D018352 |
| Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |